Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of tizanidine.

Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent- containing layer structure comprising: A) a backing layer; B) an active agent-containing layer comprising at least one silicone-containing polymer; C) a skin contact layer; and wherein the skin contact layer is an adhesive layer comprising a silicone gel adhesive.

Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising: A) a backing layer; B) an active agent-containing layer comprising at least one acrylic polymer; C) a skin contact layer; and wherein the skin contact layer is an adhesive layer comprising a silicone gel adhesive.

Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.

Abstract: The present invention relates to a transdermal therapeutic system (1) comprising an active-substance carrier layer (2) having at least one active-substance-containing polymer matrix (3) applied to the active-substance carrier layer (2), said matrix comprising at least one pressure-sensitive adhesive and at least one pharmacologically active substance absorbable through human or animal skin, and an adhesive carrier layer (6) coated as completely as possible with an active-substance-free pressure-sensitive adhesive (7), said adhesive carrier layer being bonded by means of the active-substance-free pressure-sensitive adhesive (7) directly to the flat side of the active-substance carrier layer (2) facing away from the active-substance-containing polymer matrix (3), wherein the adhesive carrier layer (6) projecting circumferentially beyond the edge of the active-substance carrier layer (2), wherein the system is characterized in that between the active-substance-containing polymer matrix (3) and the active-sub

Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; B) a rivastigmine-containing layer comprising at least one acrylic polymer; and C) a skin contact layer comprising at least one styrene-isoprene-styrene block copolymer and at least one tackifier.

Abstract: Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer comprising a therapeutically effective amount of the active agent, and C) a skin contact layer comprising at least one silicone acrylic hybrid polymer.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer, wherein the active agent-containing layer comprises a therapeutically effective amount of the active agent and at least one silicone acrylic hybrid polymer, and C) a skin contact layer.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer, wherein the active agent-containing layer comprises a therapeutically effective amount of the active agent and at least one silicone acrylic hybrid polymer, and C) a skin contact layer, wherein the skin contact layer comprises at least one silicone acrylic hybrid polymer.

Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.

Abstract: There is described a topical therapeutic system, comprising a backing layer, a matrix layer containing active ingredient which contains at least one active ingredient, at least one permeability enhancer, at least one non-occlusive adhesive, at least one antioxidant, and at least one cross-linking agent, and also an occlusion-producing layer containing at least one adhesive, which layer is located between the matrix layer containing active ingredient and the backing layer.

Abstract: Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

Abstract: Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

Abstract: Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.